• Kristie L Foley, Emily V Dressler, Kathryn E Weaver, Erin L Sutfin, David P Miller, Christina Bellinger, Carol Kittel, Rebecca J Stone, W Jeffrey Petty, Stephanie R Land, John G Spangler, Glenn J Lesser, Caroline Chiles, and Optimizing Lung Screening Trial Writing Team.
• Department of Implementation Science, Wake Forest University School of Medicine, Winston-Salem, NC. Electronic address: kfoley@wakehealth.edu.
• Chest. 2023 Aug 1; 164 (2): 531543531-543.

BackgroundOne-half of all people who undergo lung cancer screening (LCS) currently use tobacco. However, few published studies have explored how to implement effective tobacco use treatment optimally during the LCS encounter.Research QuestionWas the Optimizing Lung Screening intervention (OaSiS) effective at reducing tobacco use among patients undergoing LCS in community-based radiology facilities?Study Design And MethodsThe OaSiS study (National Cancer Institute [NCI] Protocol No.: WF-20817CD) is an effectiveness-implementation hybrid type II cluster randomized trial of radiology facilities conducted in partnership with the Wake Forest National Cancer Institute Community Oncology Research Program research base. We randomly assigned 26 radiology facilities in 20 states to the intervention or usual care group. Staff at intervention facilities implemented a variety of strategies targeting the clinic and care team. Eligible patient participants were aged 55 to 77 years undergoing LCS and currently using tobacco. Of 1,094 who completed a baseline survey (523 intervention group, 471 control group) immediately before the LCS appointment, 956 completed the 6-month follow-up (86% retention rate). Fifty-four percent of those who reported not using tobacco at 6 months completed biochemical verification via mailed cotinine assay. Generalized estimating equation marginal models were used in an intention-to-treat analysis to predict 7-day tobacco use abstinence.ResultsThe average self-reported abstinence among participants varied considerably across facilities (0%-27%). Despite a significant increase in average cessation rate over time (0% at baseline to approximately 13% at 6 months; P < .0001), tobacco use did not differ by trial group at 14 days (OR, 0.96; 95% CI, 0.46-1.99; P = .90), 3 months (OR, 1.17; 95% CI, 0.69-1.99; P = .56), or 6 months (OR, 0.97; 95% CI, 0.65-1.43; P = .87).InterpretationThe OaSiS trial participants showed a significant reduction in tobacco use over time, but no difference by trial arm was found.Trial RegistryClinicalTrials.gov; No.: NCT03291587; URL: www.Clinicaltrialsgov.Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.

15 keywords...

hide…